Citations

Clear

4847 citation(s) found for "Tu, Eric".

Promoter-proximal transcription factor binding is transcriptionally active when coupled with nucleosome repositioning in immediate vicinity
Yadav, Vinod Kumar , Thakur, Ram Krishna, Eckloff, Bruce W., Baral, Aradhita, Singh, Ankita, Halder, Rashi , Kumar, Akinchan, Alam, Mohammad P., Kundu, Tapas K. , Pandita, Raj K., Pandita, Tej K. , Wieben, Eric D. , Chowdhury, Shantanu , Eckloff, Bruce

Mayo Clinic

Nucleic Acids Research | August 1, 2014 | Volume: 42 | Issue: 15 | Pages: 9602-9611

10.1093/nar/gku596 | PMID 25081206 Get It

Abstract Previous studies have analyzed patterns of transcription, transcription factor (TF) binding or mapped nucleosome occupancy across the genome. These suggest that the three aspects are genetically connected but the cause and effect relationships are still unknown. For example, physiologic TF binding studies involve many TFs, consequently, it is difficult to assign nucleosome reorganization to the binding site occupancy of any particular TF. Therefore, several aspects remain unclear: does TF binding influence nucleosome (re)organizations locally or impact the chromatin landscape at a more global level; are all or only a fraction of TF binding a result of reorganization in nucleosome occupancy and do all TF binding and associated changes in nucleosome occupancy result in altered gene expression? With these in mind, following characterization of two states (before and after induction of a single TF of choice) we determined: (i) genomic binding sites of the TF, (ii) promoter nucleosome occupancy and (iii) transcriptome profiles. Results demonstrated that promoter-proximal TF binding influenced expression of the target gene when it was coupled to nucleosome repositioning at or close to its binding site in most cases. In contrast, only in few cases change in target gene expression was found when TF binding occurred without local nucleosome reorganization.
Complications after oncologic scalp reconstruction: A 139-patient series and treatment algorithm
Janus, Jeffrey R. , Peck, Brandon W., Tombers, Nicole M. , Moore, Eric J. , Price, Daniel L.

Mayo Clinic

The Laryngoscope | July 30, 2014 | Volume: 125 | Issue: 3 | Pages: 582-588

10.1002/lary.24855 | PMID 25073781 Get It

Cardiovascular Risk and Acute Coronary Syndrome in Giant Cell Arteritis: A Population‐Based Retrospective Cohort Study
Udayakumar, Prabhu D., Crowson, Cynthia S. , Warrington, Kenneth J. , Matteson, Eric L. , Chandran, Arun Kumar , Warrington, Kenneth J

Mayo Clinic

Arthritis Care & Research | July 29, 2014 | Volume: 67 | Issue: 3 | Pages: 396-402

10.1002/acr.22416 | PMID 25074472 Get It

Objective To assess the occurrence of acute coronary syndrome (ACS) in patients with giant cell arteritis (GCA) compared to subjects without GCA. Methods We retrospectively reviewed a population‐based incidence cohort of Olmsted County, Minnesota residents with GCA diagnosed in 1950–2009. We compared this cohort with a cohort of patients without GCA of similar age, sex, and calendar year from the same population. Results The study included 245 patients with GCA and 245 non‐GCA subjects. The mean ± SD Framingham cardiovascular risk score was 30% ± 19% in GCA patients and 34% ± 23% in non‐GCA subjects ( P = 0.096) at the incidence/index date. Diabetes mellitus was significantly less common in GCA patients than non‐GCA subjects at the index date. The mean high‐density lipoprotein was higher and triglycerides were lower, with fewer patients taking lipid‐lowering medications in the GCA cohort compared to the non‐GCA cohort at the index date. During followup, no difference between the 2 cohorts was noted in the overall rate of ACS events (hazard ratio 0.74, 95% confidence interval 0.44–1.26). Overall thrombosis in myocardial infarction scores were similar in both cohorts. Revascularization procedures were done less frequently in GCA than in non‐GCA subjects (19% versus 50%; P = 0.015). Post‐ACS hospital length of stays and complications were similar in both cohorts. Conclusion Multiple cardiovascular risk factors are less atherogenic at incidence of GCA. There is no overall increased risk of ACS in patients with GCA.
Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease
Hess, Paul L. , Hellkamp, Anne S., Sanders, Gillian D, Al‐Khalidi, Hussein R. , Curtis, Lesley H. , Pun, Patrick H. , Curtis, Jeptha P. , Anstrom, Kevin J. , Hammill, Stephen C., Al-Khalidi, Hussein R, Hammill, Bradley G, Al-Khatib, Sana M, Peterson, Eric D. , Hammill, Bradley G. , Al‐Khatib, Sana M.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 19, 2014 | Volume: 7 | Issue: 5 | Pages: 793-799

10.1161/circep.114.001455 | PMID 25038119 Get It

Background— Guidelines recommend that implantable cardioverter-defibrillator (ICD) candidates have an estimated longevity of ≥1 year. Longevity can be affected by chronic kidney disease (CKD). Methods and Results— Using the National Cardiovascular Data Registry ICD registry linked with the Social Security Death Master File, we assessed the rate of death after primary prevention ICD placement between January 1, 2006, and December 31, 2007, according to CKD stage. Using Cox models, we identified factors associated with death among patients with CKD. Compared with patients without CKD (n=26 056), those with CKD (n=21 226) were older, less commonly men, more often white, and more frequently had comorbid illness. Compared with patients without CKD, patients with a glomerular filtration rate 30 to 60, glomerular filtration rate <30, and end-stage renal disease on dialysis had a higher risk of death after ICD placement (hazard ratio, 2.08; 95% confidence interval, 1.99–2.18; P <0.0001; hazard ratio, 4.20; 95% confidence interval, 3.92–4.50; P <0.0001; and hazard ratio, 4.80; 95% confidence interval, 4.46–5.17; P <0.0001, respectively). Corresponding 1-year death rates were 4.4%, 9.1%, 20.2%, and 22.4%. Among patients with CKD, factors associated with increased risk of death included CKD severity, age >65 years, heart failure symptoms, diabetes mellitus, lung disease, serum sodium <140 mEq/L, atrial fibrillation or flutter, and a lower ejection fraction. Conclusions— The risk of death after primary prevention ICD placement is proportional to CKD severity. Among patients with CKD, several factors are prognostically significant and could inform clinical decision making on primary prevention ICD candidacy.
Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high‐risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin‐amphotericin co
Abidi, Maheen Z. , Sohail, M. Rizwan , Wilhelm, Mark , Wengenack, Nancy L. , Brumble, Lisa , Shah, Harshal , Hata, D. Jane , McCullough, Ann E. , Wendel, Amy J., Vikram, Holenarasipur R. , Kusne, Shimon , Litzow, Mark R. , Letendre, Louis, Lahr, Brian D. , Poeschla, Eric M. , Walker, Randall C., Cummins, Nathan W. , Vikram, Holenarasipur R. , Sohail, M Rizwan , Abidi, Maheen Z , Abidi, Maheen Z

Mayo Clinic

Mycoses | July 18, 2014 | Volume: 57 | Issue: 11 | Pages: 687-698

10.1111/myc.12222 | PMID 25040241 Get It

SummaryAs invasive mucormycosis (IM) numbers rise, clinicians suspect prior voriconazole worsens IM incidence and severity, and believe combination anti‐fungal therapy improves IM survival. To compare the cumulative incidence (CI), severity and mortality of IM in eras immediately before and after the commercial availability of voriconazole all IM cases from 1995 to 2011 were analysed across four risk‐groups (hematologic/oncologic malignancy (H/O), stem cell transplantation (SCT), solid organ transplantation (SOT) and other), and two eras, E1 (1995–2003) and E2, (2004–2011). Of 101 IM cases, (79 proven, 22 probable): 30 were in E1 (3.3/year) and 71 in E2 (8.9/year). Between eras, the proportion with H/O or SCT rose from 47% to 73%, while ‘other’ dropped from 33% to 11% (P = 0.036). Between eras, the CI of IM did not significantly increase in SCT (P = 0.27) or SOT (P = 0.30), and patterns of anatomic location (P = 0.122) and surgical debridement (P = 0.200) were similar. Significantly more patients received amphotericin‐echinocandin combination therapy in E2 (31% vs. 5%, P = 0.01); however, 90‐day survival did not improve (54% vs. 59%, P = 0.67). Since 2003, the rise of IM reflects increasing numbers at risk, not prior use of voriconazole. Frequent combination of anti‐fungal therapy has not improved survival.
Dixon‐type and subtraction‐type contrast‐enhanced magnetic resonance angiography: A theoretical and experimental comparison of SNR and CNR
Stinson, Eric G. , Trzasko, Joshua D. , Weavers, Paul T., Riederer, Stephen J.

Mayo Clinic

Magnetic Resonance in Medicine | July 17, 2014 | Volume: 74 | Issue: 1 | Pages: 81-92

10.1002/mrm.25374 | PMID 25043453 Get It

PurposeThe purpose of this work is to compare the behavior of the signal‐to‐noise ratio (SNR) and contrast‐to‐noise ratio (CNR) in contrast‐enhanced MR angiography with background suppression performed by either a Dixon‐type or subtraction‐type method.Theory and MethodsTheoretical expressions for the SNR and CNR for both background suppression techniques were derived. The theoretical Dixon:subtraction SNR and CNR ratios were compared to empirical ratios measured from phantom and in vivo studies for Dixon techniques utilizing one, two, and three echoes. Specifically, the SNR and CNR ratios were compared as the concentration of contrast material in the blood changed.ResultsEmpirical measurements of the SNR and CNR ratios compared favorably with the ratios predicted by theory. As the contrast concentration was reduced, the SNR advantage of the Dixon techniques increased asymptotically. In the ideal case, the SNR improvement over subtraction contrast‐enhanced MR angiography was at least twofold for one‐ and two‐echo Dixon techniques and at least a factor of for the three‐echo Dixon technique.ConclusionExpressions showing a contrast concentration‐dependent SNR and CNR improvement of at least a factor of two when Dixon‐type contrast‐enhanced MR angiography is used in place of subtraction‐type contrast‐enhanced MR angiography were derived and validated with phantom and in vivo experiments. Magn Reson Med 74:81–92, 2015. © 2014 Wiley Periodicals, Inc.
De novo acute myeloid leukemia with 20–29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study
Hasserjian, Robert P. , Campigotto, Federico, Klepeis, Veronica, Fu, Bin , Wang, Sa A. , Bueso‐Ramos, Carlos E. , Cascio, Michael J. , Soderquist, Craig , Bagg, Adam , Yan, Jiong , Ochs, Rachel, Orazi, Attilio , Moore, Frank, Mahmoud, Amer, George, Tracy I. , Foucar, Kathryn , Odem, Jamie L., Booth, Cassie, Morice, William G. , Stone, Richard M. , Rogers, Heesun J. , Hsi, Eric D. , Morice, William George , DeAngelo, Daniel J. , Steensma, David P. , Neuberg, Donna , Arber, Daniel A. , Cascio, M J , George, Tracy I , Orazi, Attilio

Mayo Clinic

American Journal of Hematology | July 17, 2014 | Volume: 89 | Issue: 11 | Pages: No page available

10.1002/ajh.23808 | PMID 25042343 Get It

It is controversial whether acute myeloid leukemia (AML) patients with 20–29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged >50 years, including 142 RAEBT and 429 with ≥30% blasts (AML30), as well as 151 patients with 10–19% BM blasts (RAEB2). RAEBT patients were older and had lower white blood count, but higher hemoglobin, platelet count, and karyotype risk scores compared to AML30, while these features were similar to RAEB2. FLT3 and NPM1 mutations and monocytic morphology occurred more commonly in AML30 than in RAEBT. RAEBT patients were treated less often with induction therapy than AML30, whereas allogeneic stem cell transplant frequency was similar. The median and 4‐year OS of RAEBT patients were longer than those of AML30 patients (20.5 vs 12.0 months and 28.6% vs 20.4%, respectively, P = 0.003); this difference in OS was manifested in patients in the intermediate UKMRC karyotype risk group, whereas OS of RAEBT patients and AML30 patients in the adverse karyotype risk group were not significantly different. Multivariable analysis showed that RAEBT (P < 0.0001), hemoglobin (P = 0.005), UKMRC karyotype risk group (P = 0.002), normal BM karyotype (P = 0.004), treatment with induction therapy (P < 0.0001), and stem cell transplant (P < 0.0001) were associated with longer OS. Our findings favor considering de novo RAEBT as a favorable prognostic subgroup of AML. Am. J. Hematol. 89:E193–E199, 2014. © 2014 Wiley Periodicals, Inc.
Selection and evaluation of optimal two‐dimensional CAIPIRINHA kernels applied to time‐resolved three‐dimensional CE‐MRA
Weavers, Paul T., Borisch, Eric A. , Riederer, Stephen J.

Mayo Clinic

Magnetic Resonance in Medicine | July 15, 2014 | Volume: 73 | Issue: 6 | Pages: 2234-2242

10.1002/mrm.25366 | PMID 25046590 Get It

PurposeTo develop and validate a method for choosing the optimal two‐dimensional CAIPIRINHA kernel for subtraction contrast‐enhanced MR angiography (CE‐MRA) and estimate the degree of image quality improvement versus that of some reference acceleration parameter set at R ≥ 8.MethodsA metric based on patient‐specific coil calibration information was defined for evaluating optimality of CAIPIRINHA kernels as applied to subtraction CE‐MRA. Evaluation in retrospective studies using archived coil calibration data from abdomen, calf, foot, and hand CE‐MRA exams was accomplished with an evaluation metric comparing the geometry factor (g‐factor) histograms. Prospective calf, foot, and hand CE‐MRA studies were evaluated with vessel signal‐to‐noise ratio (SNR).ResultsRetrospective studies show g‐factor improvement for the selected CAIPIRINHA kernels was significant in the feet, moderate in the abdomen, and modest in the calves and hands. Prospective CE‐MRA studies using optimal CAIPIRINHA show reduced noise amplification with identical acquisition time in studies of the feet, with minor improvements in the hands and calves.ConclusionA method for selection of the optimal CAIPIRINHA kernel for high (R ≥ 8) acceleration CE‐MRA exams given a specific patient and receiver array was demonstrated. CAIPIRINHA optimization appears valuable in accelerated CE‐MRA of the feet and to a lesser extent in the abdomen. Magn Reson Med 73:2234–2242, 2015. © 2014 Wiley Periodicals, Inc.